Zhu 2017.

Methods	Design: parallel RCT Randomisation method: not reported Blinding: no Power calculation: no Dropouts/withdrawals: no
Participants	People with primary liver cancer who were eligible for receiving transarterial chemoembolization (TACE), and were diagnosed with Chinese medicine syndrome of stagnation of liver qi and spleen deficiency Number (treatment/control): 60 (30/30) Mean age: 47.84 Gender (M/F): 44/16 Country: Guangxi province, China Setting: hospital
Interventions	Indirect moxa box on ginger + conventional medicine vs conventional medicine Treatment group Indirect moxa box on ginger Indirect moxa box on ginger was placed on the bilateral acupoints ST36 (zusanli) and KI 1 (yongquan), 30 minutes, once per day Treatment duration: 8 days (1 day before TACE) Conventional treatment Symptomatic treatment TACE Control group Conventional treatment Symptomatic treatment TACE
Outcomes	Qol (EORTC QLQ‐c30) at the end of treatment
Notes	—
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	No relevant description
Incomplete outcome data (attrition bias) All outcomes	Low risk	There was no loss to follow‐up. All participants were included in the analysis.
Selective reporting (reporting bias)	Unclear risk	Limited outcome measures were reported.
Other bias	Unclear risk	Baseline characteristic data were comparable.
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding
Blinding of outcome assessment (detection bias) Subjective outcomes	High risk	No blinding
Blinding of outcome assessment (detection bias) Objective outcomes	Unclear risk	No objective outcome was reported.

5‐FU: fluorouracil; CD3: lymphocyte count; CD4: T‐helper cell; CD8: cytotoxic T cell; CTCAE: Common Terminology Criteria for Adverse Events; EORTC QLQ‐C30: European Organization for Research and Treatment of Cancer QoL Questionnaire; FACT‐G 4.0: Functional Assessment of Cancer Therapy ‐ General; G‐CSF: granulocyte‐colony stimulating factor; Hb: haemoglobin; Ig: immunoglobulin; im: intramuscular; iv: intravenous; NVB: vinorelbine; PDD: cis‐platinum (II) diamminedichloride; PWB: physical well‐being; QoL: quality of life; RCT: randomised controlled trial; WBC: white blood cells; WHO: World Health Organization.